Filtern Sie alle Angebote nach Fachbereich
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries. The disease is very heterogeneous with some patients showing extremely slow progression while others proceed rapidly into advanced disease stages and require immediate treatment. Despite considerable improvement of therapeutic strategies in the last decade, CLL remains incurable by conventional chemoimmuno-therapies. The development of new treatment options remains an important goal.
The present invention provides compounds acting as an effective and selective medicament for the treatment of neoplastic diseases or proliferative disorders, in particular compounds which induce selectively apoptosis of degenerated cells providing reduced side effects in living organisms.
The compounds of the present invention are characterized by a high selectivity towards neoplastic cells. CLL cells show a higher sensitivity towards the compounds than PBMCs opening a therapeutic window. The EC50 for CLL cells is in the lower micromolar range.
Furthermore, compounds have proven activity on different CLL populations.
The activity against CLL cells has been shown in a xenograft model of CLL.
It has been shown that compounds may be suitable for the treatment of other neoplasias.
On behalf of the University of Cologne, we are offering this opportunity for licensing.
A PCT application is pending.
Gehrke I et al.: Ther Adv Hematol. 2011 Oct;2(5):279-89
Razavi R et al.: Clin Cancer Res. 2011 Jan 15;17(2):286-93